Hormone
FTC to Sue Major PBMs Over Insulin and Drug Prices Amid Anticompetitive Concerns
FTC, PBMs, Insulin Prices, Drug Prices, Anticompetitive Practices, Pharmacy Benefit Managers, Health Companies, Legal Action
Zealand Raises $1 Billion to Advance Amylin Obesity Drug and Seek Partnership
Zealand Pharma, Obesity, Amylin, Weight Loss, $1 Billion Raise, Partnership
Vertex Announces Positive Results for VX-880 in Type 1 Diabetes Treatment
Vertex Pharmaceuticals, VX-880, Type 1 Diabetes, Stem Cell Therapy, Insulin Independence, Severe Hypoglycemic Events
Crinetics’s Atumelnant Shows Promising Early Results in Congenital Adrenal Hyperplasia Treatment
Crinetics, Atumelnant, congenital adrenal hyperplasia, early data, treatment, clinical trial, cortisol, androgens, ACTH, adrenal glands.
Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk
Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.
Ascendis Hormone Replacement Therapy Faces Setback with FDA Review Extension
Ascendis Pharma, hormone replacement therapy, FDA review, delay, three-month extension.
From Alpine’s Elite Data Room to Vertex’s VIP: A Shift in Biotech Dominance
Alpine, Vertex, biotech, data room, exclusivity, VIP, shift, dominance.
Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo
Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)
Medicare Coverage Gap Linked to Reduced Prescription Rates for GLP-1 Weight Loss Drugs
GLP-1 drugs, Medicare coverage gap, Lower prescription rates, Obesity treatment, Semaglutide (Wegovy), Tirzepatide (Mounjaro), Liraglutide (Saxenda), Healthcare costs, Truveta study